机译:单臂的四年随访,II期II II II临床试验与Rituximab(IR IR)复发/难治性地幔细胞淋巴瘤(MCL MCL)的患者
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer CenterHouston TX USA;
ibrutinib; MCL; rituximab; mantle cell lymphoma; BTK;
机译:单臂的四年随访,II期II II II临床试验与Rituximab(IR IR)复发/难治性地幔细胞淋巴瘤(MCL MCL)的患者
机译:硼替佐米难治后复发或进展的套细胞淋巴瘤患者的单剂来那度胺:II期MCL-001(EMERGE)研究。
机译:在患有甲状腺细胞淋巴瘤患者的单孕醇Lenalidomide后或者在硼替佐米的难治性或难治性:IIMCL-001(出现)的研究。
机译:俄罗斯艾滋病毒/艾滋病疫苗的第一次临床试验 - II期
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:硼替佐米难治后复发或进展的套细胞淋巴瘤患者的单剂来那度胺:II期MCL-001(EMERGE)研究
机译:单臂的四年随访,II期与Rituximab(IR)复发/难治性地幔细胞淋巴瘤(MCL)的患者